Lv2
110 积分 2021-11-25 加入
Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation Simulations
1天前
已完结
Defining a new nomenclature for the structures of active and inactive kinases
12天前
已完结
Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer
14天前
已完结
MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
15天前
已完结
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
19天前
已完结
SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD
19天前
已完结
Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer
19天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
23天前
已完结
Beyond First-Generation KRAS Inhibitors: BBO-8520 Tests the Dual Mechanism Hypothesis
27天前
已关闭
Targeting cancer with small-molecule pan-KRAS degraders
29天前
已完结
皖公网安备34019202002308
